Methods of evaluating phosphatase inhibitors
AssigneeAstellas Pharma Inc.
InventorsMasahiko Morita, Hiroyuki Arakawa, Mayako Yamazaki, Susumu Satoh, Shintaro Nishimura, Yasuhiro Kita, Takao Yamazaki
Life of this patent
Estimating the term…
Loading patent…
AssigneeAstellas Pharma Inc.
InventorsMasahiko Morita, Hiroyuki Arakawa, Mayako Yamazaki, Susumu Satoh, Shintaro Nishimura, Yasuhiro Kita, Takao Yamazaki
Estimating the term…
The present invention identified OVARC1000473 (SEQ ID NO: 1) and NT2RM1000377 (SEQ ID NO: 3) as clones showing suppression of CREB activation by forskolin, and provides evaluation methods using these genes, and/or proteins encoded by these genes. Furthermore, these proteins were found to enhance cell damage. Compounds that can be screened based on the evaluation methods of this invention are useful as agents for inhibiting the CREB dephosphorylation reaction, agents for suppressing enhancement of cell damage, and preventive and therapeutic agents for memory disorders and/or neurodegenerative disorders.
A method for detecting a compound which inhibits dephosphorylation of a cAMP responsive element binding protein (CREB), wherein the method comprises
Dependencies are inferred from the claim text.